Assess the Long-term Safety and Efficacy of Pravafenix Cap. in Korean Patients With Dyslipidemia: a Multicenter, Prospective, Observational Study
Latest Information Update: 04 Jul 2022
Price :
$35 *
At a glance
- Drugs Fenofibrate/pravastatin (Primary)
- Indications Dyslipidaemias
- Focus Adverse reactions
- Sponsors Yooyoung Pharmaceutical
- 30 Aug 2017 Planned initiation date changed from 30 Jul 2017 to 30 Aug 2017.
- 13 Jul 2017 New trial record